BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 05/04/22

BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting PR Newswire NurOwn-derived exosomes showed more potent anti-inflammatory effects in vitro compared to naïve mesenchymal stem cell-derived exosomes ...

BrainStorm Announces Upcoming Scientific Conference Presentations PR Newswire Data on MSC-NTF exosome technology at ISCT 2022 and ISEV 2022 conferences NurOwn® CFS biomarker analysis to be presented at ALS Drug Development Summit NEW YORK , May 3...

BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update PR Newswire NEW YORK , May 2, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegener...

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) traded at a new 52-week high today of $17.90. Approximately 46.2 million shares have changed hands today, as compared to an average 30-day volume of 62,000 shares. Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is ...

BrainStorm Cell Therapeutics Inc. (BCLI) Q4 2021 Results Earnings Conference Call March 28, 2022, 08:00 AM ET Company Participants Michael Wood - Investor Relations, LifeSci Advisors Chaim Lebovits - Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Ralph Kern - President ...

Brainstorm Cell Therapeutics (BCLI -3.8%) stock declined following its FY21 results. Full year 2021 net loss amounted to -$24.46M, compared to net loss of -$31.8M in 2020. Research and development expenses decreased to $15.24M, compared to $22.33M in 2020. General and administrative expenses ...

Brainstorm Cell Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT PR Newswire NEW YORK , March 28, 2022 /PRNewswire/ -- Brainstorm Cell Therapeut...

BrainStorm Cell Therapeutics press release (NASDAQ:BCLI): FY GAAP EPS of -$0.68 beats by $0.11. Cash, cash equivalents, and short-term bank deposits of approximately $22.1M. "We began 2022 with strong momentum and Phase 3 data showing that NurOwn® appears to deliver meaningful clinical b...

BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update BrainStorm continues to collect and leverage expert feedback as it pursues the optimal path forward to provide broad access to NurOwn® for patients with ALS Announced...

BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update PR Newswire NEW YORK , March 14, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for ...